PURPOSE: Ibrutinib is an oral Bruton's tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) patients with at least one prior therapy. We developed a population pharmacokinetic (PK) model for ibrutinib in patients. METHODS: Ibrutinib PK data (3,477 observations/245 patients) were available from the following clinical studies: (1) A phase I dose-escalation study in recurrent B cell malignancies (dose levels of 1.25-12.5 mg/kg/day and fixed dose of 560 mg/day); (2) a phase II study in MCL (fixed dose level of 560 mg/day); (3) a phase Ib/II dose-finding study in CLL (fixed dose levels of 420 and 840 mg/day). Different compartmental PK models were explored using nonlinear mixed effects modeling. RESULTS: A two-compartment PK model with sequential zero-first-order absorption and first-order elimination was able to characterize the PK of ibrutinib. The compound was rapidly absorbed, had a high oral plasma clearance (approximately 1,000 L/h) and a high apparent volume of distribution at steady state (approximately 10,000 L). PK parameters were not dependent on dose, study, or clinical indication. The fasting state was characterized by a 67 % relative bioavailability compared with the meal conditions used in the trials and administration after a high-fat meal. Body weight and coadministration of antacids marginally increased volume of distribution and duration of absorption, respectively. CONCLUSIONS: The proposed population PK model was able to describe the plasma concentration-time profiles of ibrutinib across various trials. The linear model indicated that the compound's PK was dose independent and time independent.
RCT Entities:
PURPOSE:Ibrutinib is an oral Bruton's tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) patients with at least one prior therapy. We developed a population pharmacokinetic (PK) model for ibrutinib in patients. METHODS:Ibrutinib PK data (3,477 observations/245 patients) were available from the following clinical studies: (1) A phase I dose-escalation study in recurrent B cell malignancies (dose levels of 1.25-12.5 mg/kg/day and fixed dose of 560 mg/day); (2) a phase II study in MCL (fixed dose level of 560 mg/day); (3) a phase Ib/II dose-finding study in CLL (fixed dose levels of 420 and 840 mg/day). Different compartmental PK models were explored using nonlinear mixed effects modeling. RESULTS: A two-compartment PK model with sequential zero-first-order absorption and first-order elimination was able to characterize the PK of ibrutinib. The compound was rapidly absorbed, had a high oral plasma clearance (approximately 1,000 L/h) and a high apparent volume of distribution at steady state (approximately 10,000 L). PK parameters were not dependent on dose, study, or clinical indication. The fasting state was characterized by a 67 % relative bioavailability compared with the meal conditions used in the trials and administration after a high-fat meal. Body weight and coadministration of antacids marginally increased volume of distribution and duration of absorption, respectively. CONCLUSIONS: The proposed population PK model was able to describe the plasma concentration-time profiles of ibrutinib across various trials. The linear model indicated that the compound's PK was dose independent and time independent.
Authors: AnnaLynn M Williams; Andrea M Baran; Carla Casulo; Patrick Reagan; Jonathan W Friedberg; Margaret Helber; Jeremiah Moore; Elizabeth Baloga; Clive S Zent; Paul M Barr Journal: Clin Lymphoma Myeloma Leuk Date: 2018-10-13
Authors: Sean D Reiff; Rose Mantel; Lisa L Smith; J T Greene; Elizabeth M Muhowski; Catherine A Fabian; Virginia M Goettl; Minh Tran; Bonnie K Harrington; Kerry A Rogers; Farrukh T Awan; Kami Maddocks; Leslie Andritsos; Amy M Lehman; Deepa Sampath; Rosa Lapalombella; Sudharshan Eathiraj; Giovanni Abbadessa; Brian Schwartz; Amy J Johnson; John C Byrd; Jennifer A Woyach Journal: Cancer Discov Date: 2018-08-09 Impact factor: 39.397
Authors: Silvia Maria Lavezzi; Jan de Jong; Martine Neyens; Paula Cramer; Fatih Demirkan; Graeme Fraser; Nancy Bartlett; Marie-Sarah Dilhuydy; Javier Loscertales; Abraham Avigdor; Simon Rule; Olga Samoilova; Andre Goy; Siddhartha Ganguly; Mariya Salman; Angela Howes; Michelle Mahler; Giuseppe De Nicolao; Italo Poggesi Journal: Pharm Res Date: 2019-05-01 Impact factor: 4.200
Authors: Paul M Barr; Jennifer R Brown; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Stephen P Mulligan; Ulrich Jaeger; Richard R Furman; Florence Cymbalista; Marco Montillo; Claire Dearden; Tadeusz Robak; Carol Moreno; John M Pagel; Jan A Burger; Samuel Suzuki; Juthamas Sukbuntherng; George Cole; Danelle F James; John C Byrd Journal: Blood Date: 2017-04-03 Impact factor: 22.113
Authors: Ronald de Vries; Johan W Smit; Peter Hellemans; James Jiao; Joseph Murphy; Donna Skee; Jan Snoeys; Juthamas Sukbuntherng; Maarten Vliegen; Loeckie de Zwart; Erik Mannaert; Jan de Jong Journal: Br J Clin Pharmacol Date: 2016-01-15 Impact factor: 4.335
Authors: Rachel A Rigg; Joseph E Aslan; Laura D Healy; Michael Wallisch; Marisa L D Thierheimer; Cassandra P Loren; Jiaqing Pang; Monica T Hinds; András Gruber; Owen J T McCarty Journal: Am J Physiol Cell Physiol Date: 2015-12-09 Impact factor: 4.249